[Medtronic-Minimed Continuous Glucose Monitoring System for patients with type 1 diabetes mellitus and gestational diabetes: efficacy and safety]
Solans M, Kotzeva A, Almazan C
Record ID 32011000241
Catalan, English
Authors' objectives:
To analyze the scientific evidence on the efficacy and safety of Medtronic-MiniMed CGMS in comparison with the self-monitoring blood glucose system in adults, pediatric patients and pregnant women with DM1, as well as pregnant women with DMG.
To propose indication criteria for the use of this technology.
Authors' recommendations:
The available evidence on improving the metabolic control of Medtronic-Minimed CGMS in real time in adults is scarce but of good quality and demonstrated a decrease in blood glucose levels, although the information about reducing the frequency of hypo- and hyperglycemias is scarce and of low quality. For the paediatric population, the limited evidence available, both in improving metabolic control and in reducing the frequency of hypo- and hyperglycemias with the retrospective Medtronic-Minimed CGMS does not allow to make conclusions about its effectiveness. Finally, there is no evidence for pregnant women. And for the security, although the studies included in the review measure it with secondary outcomes, data suggest that the system is safe and that adverse effects are mild. Considering the available evidence, the CGMS in real time should be restricted to the following potential candidates: DM1 Adults patients with a lack of glycemic control (HbA1c >=8,1%) treated with an intensive insuline therapy (Continuous subcutaneous insulin infusion or multiple insulin injections), including a 3 months review.
Details
Project Status:
Completed
Year Published:
2010
URL for published report:
http://www.gencat.cat/salut/depsan/units/aatrm/pdf/medtronic_minimed_diabetis_aiaqs_2010ca.pdf
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Spain
MeSH Terms
- Blood Glucose Self-Monitoring
- Diabetes Mellitus, Type 1
- Diabetes, Gestational
Contact
Organisation Name:
Agencia de Qualitat i Avaluacio Sanitries de Catalunya
Contact Address:
Antoni Parada, CAHTA, Roc Boronat, 81-95 (2nd floor), 08005 Barcelona, Spain, Tel. +34 935 513 928, Fax: +34 935 517 510
Contact Name:
direccio@aatrm.catsalut.net / aparada@aatrm.catsalut.net
Contact Email:
direccio@aatrm.catsalut.net / aparada@aatrm.catsalut.net
Copyright:
Catalan Agency for Health Information, Assessment and Quality (CAHIAQ)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.